AbbVie Inc. (ABBV) — SEC Filings

Latest SEC filings for AbbVie Inc. (ABBV), explained in plain English.

Sentiment Overview: 1 bearish, 40 neutral, 1 mixed

Recent Filings (42)

• AbbVie Files DEFA14A Proxy Materials on March 23, 2026 — DEFA14A · 2026-03-23T17:01:40-04:00 [neutral]
  AbbVie Inc. filed a DEFA14A on March 23, 2026, which is additional definitive proxy soliciting materials. This filing indicates that AbbVie is communicating wit
• AbbVie's Q3 Earnings Plummet 88% Amidst Aggressive R&D Investments — 10-Q · 2025-11-04T00:00:00.000Z [mixed] Risk: medium
  AbbVie Inc. reported a significant decline in net earnings for the three months ended September 30, 2025, falling to $186 million from $1,561 million in the pri
• AbbVie Inc. Files 8-K on Financials — 8-K · 2025-10-31T00:00:00.000Z [neutral] Risk: low
  AbbVie Inc. filed an 8-K on October 31, 2025, reporting on its financial condition and results of operations. The filing also includes financial statements and
• AbbVie Inc. Files 8-K on Financials and Debt — 8-K · 2025-10-03T00:00:00.000Z [neutral] Risk: low
  On October 3, 2025, AbbVie Inc. filed an 8-K report detailing its financial condition and results of operations. The filing includes information on various seni
• AbbVie Inc. Files 8-K Report — 8-K · 2025-09-11T00:00:00.000Z [neutral] Risk: low
  On September 11, 2025, AbbVie Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with a Regulation FD disclosure.
• AbbVie Q2 Earnings Dip Amid Revenue Decline, Legal Headwinds — 10-Q · 2025-08-04T00:00:00.000Z [bearish] Risk: high
  AbbVie Inc. reported total net revenues of $13.725 billion for the second quarter ended June 30, 2025, a decrease from $13.869 billion in the prior-year quarter
• AbbVie Inc. Files 8-K on Financial Operations — 8-K · 2025-07-31T00:00:00.000Z [neutral] Risk: low
  On July 31, 2025, AbbVie Inc. filed an 8-K report detailing its financial condition and results of operations. The filing includes information on various senior
• AbbVie Inc. Files 8-K on Financials and Senior Notes — 8-K · 2025-07-03T00:00:00.000Z [neutral] Risk: low
  On July 3, 2025, AbbVie Inc. filed an 8-K report detailing its financial condition and results of operations. The filing includes information on various senior
• AbbVie Inc. Files 8-K: Director Changes and Shareholder Votes — 8-K · 2025-05-13T00:00:00.000Z [neutral] Risk: low
  On May 8, 2025, AbbVie Inc. filed an 8-K report detailing several key events. The filing includes information regarding the departure and election of directors,
• 10-Q Filing — 10-Q · 2025-05-09T00:00:00.000Z [neutral]
• AbbVie Inc. Files 8-K on Financials — 8-K · 2025-04-25T00:00:00.000Z [neutral] Risk: low
  AbbVie Inc. filed an 8-K on April 25, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibit
• AbbVie Inc. Files 8-K on Financial Operations — 8-K · 2025-04-03T00:00:00.000Z [neutral] Risk: low
  On April 3, 2025, AbbVie Inc. filed an 8-K report detailing its financial condition and results of operations. The filing includes information on various senior
• AbbVie Inc. DEF 14A: Executive Compensation Details — DEF 14A · 2025-03-24T00:00:00.000Z [neutral] Risk: low
  AbbVie Inc. filed a DEF 14A with the SEC on March 24, 2025, for the fiscal year ending December 31, 2024. The filing details executive compensation and board me
• AbbVie Inc. Files 8-K Report — 8-K · 2025-02-26T00:00:00.000Z [neutral] Risk: low
  On February 26, 2025, AbbVie Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." No specific financi
• AbbVie Inc. Files 8-K: Senior Notes and Stock Details — 8-K · 2025-02-19T00:00:00.000Z [neutral] Risk: low
  On February 18, 2025, AbbVie Inc. filed an 8-K report detailing other events and financial statements. The filing includes information about its common stock an
• AbbVie Inc. Files 8-K on Officer Changes and Financials — 8-K · 2025-02-14T00:00:00.000Z [neutral] Risk: low
  AbbVie Inc. filed an 8-K on February 14, 2025, reporting on the departure of directors or certain officers, election of directors, appointment of certain office
• AbbVie Files 2024 10-K — 10-K · 2025-02-14T00:00:00.000Z [neutral] Risk: medium
  AbbVie Inc. filed its 2024 10-K on February 14, 2025, detailing its financial performance for the fiscal year ending December 31, 2024. The company, a major pla
• AbbVie Inc. Files 8-K Report — 8-K · 2025-02-05T00:00:00.000Z [neutral] Risk: low
  On January 30, 2025, AbbVie Inc. filed an 8-K report detailing "Other Events." The filing does not contain specific financial transactions or material events be
• AbbVie Inc. Files 8-K on Financials and Debt — 8-K · 2025-01-31T00:00:00.000Z [neutral] Risk: low
  On January 31, 2025, AbbVie Inc. filed an 8-K report detailing its financial condition and results of operations. The filing includes information on various sen
• AbbVie Inc. Discloses Material Impairment — 8-K · 2025-01-10T00:00:00.000Z [neutral] Risk: medium
  On January 9, 2025, AbbVie Inc. filed an 8-K report indicating a material impairment. The filing does not specify the exact amount of the impairment or the asse
• AbbVie Inc. Files 8-K on Financial Operations — 8-K · 2025-01-06T00:00:00.000Z [neutral] Risk: low
  On January 6, 2025, AbbVie Inc. filed an 8-K report detailing its financial condition and results of operations. The filing includes information on various seni
• AbbVie Inc. Files 8-K: Director and Officer Changes — 8-K · 2024-12-13T00:00:00.000Z [neutral] Risk: low
  On December 11, 2024, AbbVie Inc. (ABBV) filed an 8-K report detailing changes in its board of directors and executive compensation. The filing indicates the de
• AbbVie Inc. Files Q3 2024 10-Q Financial Report — 10-Q · 2024-11-04T00:00:00.000Z [neutral] Risk: low
  AbbVie Inc. filed its 10-Q for the period ending September 30, 2024. The filing details the company's financial performance and position, including revenue, exp
• AbbVie Inc. Files 8-K on Financials and Senior Notes — 8-K · 2024-10-30T00:00:00.000Z [neutral] Risk: low
  On October 30, 2024, AbbVie Inc. filed an 8-K report detailing its financial condition and results of operations. The filing includes information on various sen
• AbbVie Files 8-K on Financials and Senior Notes — 8-K · 2024-10-03T00:00:00.000Z [neutral] Risk: low
  On October 3, 2024, AbbVie Inc. filed an 8-K report detailing its financial condition and results of operations. The filing includes information on various seni
• AbbVie Inc. Files Routine 8-K Report — 8-K · 2024-09-10T00:00:00.000Z [neutral] Risk: low
  On September 6, 2024, AbbVie Inc. filed an 8-K report detailing amendments to its articles of incorporation or bylaws and financial statements. The filing does
• AbbVie Inc. Files Q2 2024 10-Q Report — 10-Q · 2024-08-07T00:00:00.000Z [neutral] Risk: low
  AbbVie Inc. filed its 10-Q for the period ending June 30, 2024, reporting on its financial performance. The company's fiscal year ends on December 31, 2024. Key
• AbbVie Inc. Files 8-K on Financial Operations — 8-K · 2024-07-25T00:00:00.000Z [neutral] Risk: low
  On July 25, 2024, AbbVie Inc. filed an 8-K report detailing its financial condition and results of operations. The filing includes information on various senior
• AbbVie Inc. Files 8-K on Financials and Senior Notes — 8-K · 2024-07-03T00:00:00.000Z [neutral] Risk: low
  On July 3, 2024, AbbVie Inc. filed an 8-K report detailing its financial condition and results of operations. The filing includes information on various senior
• AbbVie Files 8-K/A: Director Changes and Officer Compensation — 8-K/A · 2024-05-08T00:00:00.000Z [neutral] Risk: low
  AbbVie Inc. filed an 8-K/A on May 8, 2024, to amend a previous filing concerning the departure of Director Robert L. Parkinson Jr. and the election of Director
• 10-Q Filing — 10-Q · 2024-05-03T00:00:00.000Z [neutral]
• AbbVie Files 8-K on Financials and Debt — 8-K · 2024-04-26T00:00:00.000Z [neutral] Risk: low
  AbbVie Inc. filed an 8-K on April 26, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and exhibit
• AbbVie Inc. Files 8-K on Financial Operations — 8-K · 2024-04-03T00:00:00.000Z [neutral] Risk: low
  On April 3, 2024, AbbVie Inc. filed an 8-K report detailing its financial condition and results of operations. The filing includes information on various senior
• AbbVie Inc. Executive Compensation Details Revealed — DEF 14A · 2024-03-18T00:00:00.000Z [neutral] Risk: low
  AbbVie Inc. filed its DEF 14A on March 18, 2024, detailing executive compensation for the fiscal year ending December 31, 2023. The filing includes information
• AbbVie Details Senior Notes in Latest 8-K Filing — 8-K · 2024-02-26T00:00:00.000Z [neutral] Risk: low
  AbbVie Inc. filed an 8-K on February 26, 2024, reporting on "Other Events" and "Financial Statements and Exhibits" as of February 22, 2024. The filing details v
• AbbVie 8-K Details Officer Changes, Compensation, and Debt Structure — 8-K · 2024-02-20T00:00:00.000Z [neutral] Risk: low
  AbbVie Inc. filed an 8-K on February 20, 2024, reporting on events that occurred on February 14, 2024. The filing details information regarding the departure or
• AbbVie Files 2023 10-K, Details Operational Expenses — 10-K · 2024-02-20T00:00:00.000Z [neutral] Risk: medium
  AbbVie Inc. filed its 10-K on February 20, 2024, for the fiscal year ended December 31, 2023. The filing details the company's financial performance and operati
• SC 13G/A Filing — SC 13G/A · 2024-02-13T00:00:00.000Z [neutral]
• AbbVie 8-K: Rule 425 Filing Signals Potential Transaction — 8-K · 2024-02-12T00:00:00.000Z [neutral] Risk: medium
  AbbVie Inc. filed an 8-K on February 12, 2024, primarily to satisfy filing obligations under Rule 425 of the Securities Act, indicating written communications r
• AbbVie 8-K Details Financial Condition, Senior Notes on Feb 2 — 8-K · 2024-02-02T00:00:00.000Z [neutral]
  AbbVie Inc. filed an 8-K on February 2, 2024, reporting on its results of operations and financial condition. This filing indicates that AbbVie is providing upd
• BlackRock Amends AbbVie Stake, Remains Key Institutional Holder — SC 13G/A · 2024-01-25T00:00:00.000Z [neutral]
  BlackRock Inc. filed an amended SC 13G/A on January 25, 2024, indicating its ownership of AbbVie Inc. common stock as of December 31, 2023. This filing, Amendme
• AbbVie Updates on Financial Condition, Senior Notes Maturities — 8-K · 2024-01-05T00:00:00.000Z [neutral]
  AbbVie Inc. filed an 8-K on January 5, 2024, to report on its financial condition and results of operations. This filing specifically mentions various senior no